Back to Search
Start Over
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-371a-3p serum levels.
- Source :
-
Urologic oncology [Urol Oncol] 2024 Dec; Vol. 42 (12), pp. 455.e9-455.e13. Date of Electronic Publication: 2024 Sep 10. - Publication Year :
- 2024
-
Abstract
- Purpose: MiR-371a-3p represents a novel liquid biomarker that detects all histologies of germ-cell tumors (GCT) except teratoma. However, it is currently unclear whether miR-371a-3p results obtained directly from RT-PCR (raw Cq) or normalized for housekeeper genes and transformed into the relative quantity (RQ) value should be used and at what cut-off level. The purpose of this research was to evaluate, which values should be used, and a potential cut-off level for relapse-detection to inform subsequent studies.<br />Materials and Methods: We applied a CE-certified qRT-PCR test to measure miR-371a-3p at each follow-up visit during active surveillance in 34 men with stage I testicular GCT. MiR-371a-3p levels were calculated by the ΔΔ method.<br />Results: About 18 Patients had pure seminoma and 16 had mixed or nonseminomatous testicular GCT. Recurrences were detected in 10 patients and were correctly identified by both raw and housekeeper-normalized miR-371a-3p serum levels. The raw Cq, with a cut-off value of <28, resulted in only 1 false positive (3%), whereas RQ, with a cut-off value of >15, produced 6 false positive results (17%). Most of these false positive results normalized in subsequent measurements. The RQ approach detected recurrence in 1 patient 6 months earlier than the raw Cq approach.<br />Conclusion: Our preliminary data suggest that this CE-certified assay, using previously suggested cut-off values, is a promising method for detecting disease recurrence, provided a confirmatory second test is conducted to identify false positive results. To avoid unnecessary scans or overtreatment, we are currently validating this assay and cut-offs in a prospective cohort study.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Male
Prospective Studies
Adult
Neoplasm Staging
Middle Aged
Young Adult
Biomarkers, Tumor blood
Biomarkers, Tumor genetics
Cohort Studies
Watchful Waiting
Testicular Neoplasms blood
Testicular Neoplasms genetics
Testicular Neoplasms diagnosis
Testicular Neoplasms pathology
Neoplasms, Germ Cell and Embryonal blood
Neoplasms, Germ Cell and Embryonal genetics
Neoplasms, Germ Cell and Embryonal diagnosis
MicroRNAs blood
Neoplasm Recurrence, Local blood
Neoplasm Recurrence, Local genetics
Neoplasm Recurrence, Local diagnosis
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2496
- Volume :
- 42
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Urologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 39261117
- Full Text :
- https://doi.org/10.1016/j.urolonc.2024.07.013